Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2019 | Story Ruan Bruwer | Photo Ruan Bruwer
Braam van Wyk
Braam van Wyk, hockey high-performance manager at the University of the Free State, should gain valuable experience with the Ghana men’s hockey team.

Braam van Wyk, hockey high-performance manager at the University of the Free State (UFS), wants to plough back whatever he can at international level.

Van Wyk has been appointed as assistant coach of the Ghana men’s hockey team. It is only a part-time appointment, as they don’t play that many matches in a year. Ghana is ranked 35th in the world.  

He will assist the team in the run-up to the Africa Cup in August 2019, where they hope to perform well enough to get an opportunity to play in the Road to Tokyo qualifier for next year’s Olympic Games. 

Van Wyk currently coaches the Ghana players who are based in South Africa. 

“I see this as an opportunity to develop the players, but also for me as a coach to grow and to coach at international level. I am excited to try and add value. The plan is to implement it here at the UFS,” Van Wyk said.

He is also the head coach of the UFS men’s team since 2016, as well as the astro manager.

Learned a lot from coach dad

According to Van Wyk (32), who studied environmental management, he already started coaching in his first year of studies while he was still playing. He represented the UFS from 2006 to 2009. 

“Between 2010 and 2015, my focus shifted to umpiring and I officiated in 19 internationals of which five involved the Protea men’s team.” 

His father, also Braam, is never too far away for guidance. Braam Sr is an astute coach who stood at the helm of many teams over the years, including the Kovsie men and women. He also coached his son while he was playing for the UFS.

“While I was playing, I used to ask him a lot of questions. I learned so much from him and still approach him for advice. He has so much experience and has achieved so much.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept